References
  1. Davies JC, Cunningham S, Harris WT, et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med . 2016; 4 (2): 107- 115.
  2. Rosenfeld M, Cunningham S, Harris WT, et al. An open-label extension study of ivacaftor in children with CF and CFTR gating mutation initiating treatment at age 2-5 years (KLIMB) . J Cyst Fibros . 2019; 18 (6): 838- 843.
  3. Rosenfeld M, Wainwright C.E., Higgins M, et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.Lancet Respir Med . 2018; 6 (7): 545- 553.
  4. Berman H.B., ”Binomial Probability Distribution”, [online] Available at: https://stattrek.com/probability-distributions/Binomial URL [Accessed Date: 9/22/2023].
  5. Kimberly G. Stephenson et al., Journal of Cystic Fibrosis, https://doi.org/10.1016/j.jcf.2023.09.005 [Article in Press]
  6. Phillips I J, Rowel D J, Dewar P, and Connett G J. Faecal elastase 1: a marker of exocrine pancreatic insufficiency in cystic fibrosis. Ann Clin Biochem 1999; 36: 739-742